Principia Biopharma Inc. Common Stock
PRNB
PRNB was delisted on the 25th of September, 2020.
137 hedge funds and large institutions have $1.91B invested in Principia Biopharma Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 55 increasing their positions, 38 reducing their positions, and 14 closing their positions.
536% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $306K
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
45% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 38
16% more funds holding
Funds holding: 118 → 137 (+19)
5% more capital invested
Capital invested by funds: $1.82B → $1.91B (+$89.4M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$42.3M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$37.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$35.7M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$33.9M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$27.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$41M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$31.5M |
| 3 |
Jennison Associates
New York
|
-$25.7M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$23.1M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$18.7M |
PRNB Hedge Fund Activity: Q2 2020 in Review
137 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Principia Biopharma Inc. Common Stock (PRNB) for Q2 2020, worth a combined $1.91B — up 4.9% from $1.82B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new PRNB positions and 14 closed out — a net gain of 19 holders — while 55 added to existing stakes and 38 trimmed.
The largest buyer was BlackRock, adding an estimated $42.3M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $41M sold.
- 137 institutional investors held Principia Biopharma Inc. Common Stock (PRNB) as of Q2 2020, up from 118 in Q1 2020.
- Funds reported $1.91B of Principia Biopharma Inc. Common Stock stock for Q2 2020, up 4.9% quarter-over-quarter.
- 33 funds opened new Principia Biopharma Inc. Common Stock positions in Q2 2020 and 14 closed out, a net change of +19 holders.
- The largest Principia Biopharma Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $42.3M added.
- The largest Principia Biopharma Inc. Common Stock seller in Q2 2020 was Consonance Capital Management, an estimated $41M sold.
Based on aggregated 13F filings for Q2 2020.